This multi-state study is a real world data analyses of the effectiveness of the RSV — short for respiratory syncytial virus — vaccine. VISION Network researchers report that across the board these vaccines were highly effective in older adults, even those with immunocompromising conditions, during the 2023-24 respiratory disease season, the first season after RSV vaccine approval in the U.S.